# EDGAR Filing Document

**Accession Number:** 0000200406
**File Stem:** 0000200406-23-000028
**Filing Date:** 2023-3
**Character Count:** 3428
**Document Hash:** 9452054354452f6a5f77e041d900b2e4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000200406-23-000028.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0000200406-23-000028

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JOHNSON & JOHNSON
- **CENTRAL INDEX KEY:** 0000200406
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 221024240
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 0101

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-03215
- **FILM NUMBER:** 23770077

**BUSINESS ADDRESS:**
- **STREET 1:** ONE JOHNSON & JOHNSON PLZ
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08933
- **BUSINESS PHONE:** 732-524-2455

**MAIL ADDRESS:**
- **STREET 1:** ONE JOHNSON & JOHNSON PLZ
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08933

**____________________________________________________________________________________________________________________________________________________________**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

<sup>___________________________</sup>

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

Filed by the Registrant 🗹

Filed by a party other than the Registrant ◻

Check the appropriate box:

◻&nbsp;&nbsp;&nbsp;&nbsp;Preliminary Proxy Statement

◻&nbsp;&nbsp;&nbsp;&nbsp;Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

◻&nbsp;&nbsp;&nbsp;&nbsp;Definitive Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

🗹&nbsp;&nbsp;&nbsp;&nbsp;Definitive Additional Materials

◻&nbsp;&nbsp;&nbsp;&nbsp;Soliciting Material under § 240.14a-12

![jnjlogoredtranspa03.gif](jnjlogoredtranspa03.gif)

*(Name of Registrant as Specified In Its Charter)*

<sup>___________________________</sup>

Payment of Filing Fee (Check all boxes that apply):

🗹&nbsp;&nbsp;&nbsp;&nbsp;No fee required

◻&nbsp;&nbsp;&nbsp;&nbsp;Fee paid previously with preliminary materials.

◻&nbsp;&nbsp;&nbsp;&nbsp;Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

**SUPPLEMENT TO**

**2023 NOTICE OF ANNUAL MEETING AND PROXY STATEMENT**

**DATED MARCH 15, 2023**

**FOR THE ANNUAL MEETING OF SHAREHOLDERS**

**TO BE HELD ON APRIL 27, 2023**

This Supplement provides updated information with respect to the 2023 Annual Meeting of Shareholders (the "Annual Meeting") of Johnson & Johnson to be held on April 27, 2023.

On March 15, 2023, Johnson & Johnson commenced distribution of the Notice of Annual Meeting and Proxy Statement (the "Proxy Statement") for the Annual Meeting and notice of availability of the Proxy Statement. This Supplement should be read in conjunction with the Proxy Statement.

This Supplement is being filed to correct the following information in the Proxy Statement. On page 138, the number of shares outstanding is corrected from 3,119,842,548 to 2,598,389,867 and on page 42, the statement:

---

| | | | | |
|:---|:---|:---|:---|:---|
| 99% | Is committed to our shareholders. | is corrected to: | 94% | Is committed to our shareholders. |

---

Information on how to vote your shares, or change or revoke your prior vote or voting instruction, is available in the Proxy Statement.

<br>